Methoxamine

Perioperative hypotension is a common hemodynamic abnormality in surgical procedures. If not corrected in time, it may lead to insufficient perfusion of vital organs and increase the risk of postoperative complications. As a vasopressor of α1 adrenergic receptor agonist, methoxamine acts on the α1 receptor of vascular smooth muscle with high selectivity, and raises arterial blood pressure by constricting peripheral resistance vessels. Meanwhile, it has minimal effect on heart rate and does not increase myocardial oxygen consumption. It is especially suitable for the prevention and treatment of hypotension in scenarios such as anesthesia induction and intraspinal anesthesia, and can also be used to treat hypotension and supraventricular tachycardia caused by myocardial infarction. It is widely used in clinical practice in anesthesiology and cardiology departments.

The market size of perioperative drugs in China continues to expand. As a commonly used clinical vasopressor, the sales of methoxamine in domestic sample hospitals exceeded 1.2 billion yuan in 2023, with a compound annual growth rate of about 18% in the past three years. At present, generic drugs account for more than 95% of the domestic market, among which the top 3 enterprises account for nearly 70% of the total market share. After the centralized procurement, the price has dropped by more than 60%, and the clinical accessibility has been significantly improved, driving the rapid growth of drug consumption in primary medical institutions.

The original research enterprise of methoxamine is Eli Lilly and Company, with the original brand name Vasoxyl, and the core compound patent expired in 1999. At present, the main dosage form approved in China is methoxamine hydrochloride injection, with common specifications including 1ml:10mg and 1ml:20mg. This product has been included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by the National Medical Products Administration. Up to now, there are 17 registration entries of methoxamine API on the CDE API Registration Platform, among which 11 have been publicized with A status. More than 20 domestic enterprises have obtained approval for the marketing of methoxamine hydrochloride injection. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of methoxamine impurity reference standards, most of which are available directly from stock. Spot orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide stable reference material support for API R&D, quality research and consistency evaluation.